Jazz Pharmaceuticals plc Q4 2025 Earnings Call Summary [Yahoo! Finance]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Yahoo! Finance
Jazz Pharmaceuticals plc Q4 2025 Earnings Call Summary - Moby Strategic Evolution and Performance Drivers Achieved record annual revenue of $4.3 billion in 2025, driven by the successful launch of Modeyso and double-digit growth in the Xywav and Zepzelca franchises. Management is sharpening the corporate focus on rare disease, leveraging existing capabilities in sleep, epilepsy, and oncology to drive long-term value through internal R&D and M&A. Resolved significant legal headwinds by settling ANDA litigation for Epidiolex, extending the product's runway into the late 2030s, and settling the majority of rare sleep franchise litigation. The acquisition of Chimerix provided immediate commercial value via Modeyso and a strategic financial benefit through a deferred tax asset expected to reduce future cash taxes by over $200 million. Zanidatamab (Ziihera) is positioned as a potential new standard of care in HER2-positive cancers following Phase III data showing unprecedented
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Record Quarter And 2026 Guidance [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals (JAZZ) had its price target raised by Royal Bank Of Canada from $191.00 to $195.00. They now have an "outperform" rating on the stock.MarketBeat
- Jazz Pharmaceuticals (JAZZ) had its price target raised by Morgan Stanley from $225.00 to $226.00. They now have an "overweight" rating on the stock.MarketBeat
- Jazz Pharmaceuticals (JAZZ) had its price target raised by Wells Fargo & Company from $235.00 to $250.00. They now have an "overweight" rating on the stock.MarketBeat
JAZZ
Earnings
- 2/24/26 - Beat
JAZZ
Sec Filings
- 2/24/26 - Form 10-K
- 2/24/26 - Form 8-K
- 1/21/26 - Form 4
- JAZZ's page on the SEC website